- 10:37 AM Nifty choppy with positive bias; Infy, Sterlite, W...
- 10:34 AM Book profits in Cummins India: VK Sharma
- 10:30 AM Buy GVK Power, says VK Sharma
- 10:19 AM Buy HOEC on all declines: Mitesh Thacker
- 10:13 AM Book profit in Sesa Goa at Rs 340: Thacker
- 10:04 AM SEBI bars Pyramid Saimira for 7yrs in IPO irregula...
- 09:58 AM Pantaloon Retail may slip to Rs 265: Thacker
- 09:56 AM Sensex flat; SBI, ICICI Bank, DLF, HDFC, RComm dip
- 09:55 AM Mkt may trade sideways on quiet global cues: Udaya...
- 09:54 AM State Trading Corporation can test Rs 425: M Thack...



Treatment for obesity traditionally involves diet therapy and lifestyle modifications such as physical exercise. However, conventional therapies alone are not always sufficient in achieving desired weight loss, as they have their own limitations. The decreased food intake may lead to nutritional deficiencies and the obese may find it difficult to strictly follow the diet regimen. Hence these difficulties in long-term weight management are encouraging patients to look for more effective treatment options with guaranteed results.
Emerging anti-obesity treatment therapies such as pharmacotherapy, bariatric surgeries, as well as the use of weight loss devices will help meet the rising need to reduce the prevalence of obesity and its associated health risks.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis on Clinical Management of Obesity, then send an e-mail to Shwetha Thomas/ Samantha Unnikrishnan, Corporate Communications, at sthomas@frost.com / sunnikrishnan@frost.com with your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the overview by e-mail upon receipt of the above information.
“Pharmacotherapy, is an Food and Drug Administration (FDA) approved treatment for patients who have not responded to diet therapy and physical exercises,” states Frost & Sullivan Research Analyst Sangeetha Prabakar. “It is recommended, both, for obese individuals with a body mass index (BMI) of 30+ who do not have any associated health risks such as type 2 diabetes, heart disease, hypertension, and stroke in addition to moderately obese patients with two or more collateral conditions.”
Contd on page 2....
|
|


Today's Special Column
with Ashok Gulati
International Food Policy Research Institute , Director in Asia


-
Most Read
-
Most Viewed
- 10 companies that MF managers love
- 10 Companies that FIIs love
- Experts on stocks and sectors to pick/avoid now

- IPO scam: SEBI bars Pyramid Saimira for 7 years

- Sensex may drift down to 12500, -ve on RIL: Shankar Sharma

- Ganeshaspeaks: Market prediction for Nov 11
- Mitesh Thacker's top picks for today's trade
- What are Ashish Chugh's hidden gems for Nov?

- Nifty choppy with positive bias; Infy, Sterlite, Wipro lead
Source: Moneycontrol.com
- Book profits in Cummins India: VK Sharma
Source: CNBC-TV18
- Buy GVK Power, says VK Sharma
Source: CNBC-TV18
- Buy HOEC on all declines: Mitesh Thacker
Source: CNBC-TV18
- Kochi port urges Govt to lift palm oil import ban
Source: Business Line
- Punj Lloyd signs JV agreement with Delta Solar
Source: Business Line
- IL&FS renegotiates Maytas Infra debt package with lenders
Source: Business Line
- Neyveli Lignite to set up wind power project
Source: Business Line





















